

Disclosures

Personal Commercial (28)

Company Name Relationship Category Compensation Level	Topic Area(s)
Self	
Alnylam Consultant Fees/Honoraria Significant (>= \$5,000)	Prevention
Alnylam Research/Research Grants None (\$0)	Prevention
Amgen Research/Research Grants None (\$0) ‡ Test 2 Treat	Prevention
Amgen Consultant Fees/Honoraria Significant (>= \$5,000)	Prevention
Astra Zeneca Consultant Fees/Honoraria Significant (>= \$5,000)	Prevention
Bayer Healthcare Pharmaceuticals Research/Research Grants \$\frac{1}{2}IRIS-CKD\$ None (\$0)	Prevention
Bayer Healthcare Pharmaceuticals Consultant Fees/Honoraria Modest (<\$5,000)	Prevention
Boerhinger Ingelheim Consultant Fees/Honoraria Significant (>= \$5,000)	Prevention
Boerhinger Ingelheim Research/Research Grants None (\$0) \ddagger IRIS-CKD	Prevention
Corcept Consultant Fees/Honoraria Significant (>= \$5,000)	Prevention
Corsera Consultant Fees/Honoraria Significant (>= \$5,000)	Prevention
Eli Lilly and Company Research/Research Grants \$\frac{1RIS-CKD}{}\$	Prevention
Eli Lilly and Company Consultant Fees/Honoraria Significant (>= \$5,000)	Prevention
Esperion Consultant Fees/Honoraria Significant (>= \$5,000)	Prevention
Janssen Pharmaceuticals, Inc Data Safety Monitoring Board None (\$0)	Arrhythmias and Clinical EP
Merck & Co., Inc. Consultant Fees/Honoraria Significant (>= \$5,000)	Prevention
Merck & Co., Inc. Research/Research Grants None (\$0)	Prevention
Miga Health Stock Significant (>= \$5,000)	Prevention
New Amsterdam Consultant Fees/Honoraria Significant (>= \$5,000)	
	Prevention
Novartis Data Safety Monitoring Board Significant (>= \$5,000)	Prevention Prevention
Novartis Data Safety Monitoring Board Significant (>= \$5,000) Novartis Corporation Research/Research Grants † VICTORION-INCLUSION; LATAM-LOWERS None (\$0)	
Novartis Corporation Research/Research Grants None (\$0)	Prevention
Novartis Corporation Research/Research Grants † VICTORION-INCLUSION; LATAM-LOWERS None (\$0)	Prevention Prevention
Novartis Corporation Research/Research Grants † VICTORION-INCLUSION; LATAM-LOWERS Novartis Corporation Consultant Fees/Honoraria Significant (>= \$5,000)	Prevention Prevention Prevention
Novartis Corporation Research/Research Grants # VICTORION-INCLUSION; LATAM-LOWERS None (\$0) Novartis Corporation Consultant Fees/Honoraria Significant (>= \$5,000) Novo Nordisk Inc. Research/Research Grants Significant (>= \$5,000)	Prevention Prevention Prevention Prevention
Novartis Corporation Research/Research Grants # VICTORION-INCLUSION; LATAM-LOWERS Novartis Corporation Consultant Fees/Honoraria Significant (>= \$5,000) Novo Nordisk Inc. Research/Research Grants Significant (>= \$5,000) Novo Nordisk Inc. Consultant Fees/Honoraria Significant (>= \$5,000)	Prevention Prevention Prevention Prevention
Novartis Corporation Research/Research Grants # VICTORION-INCLUSION; LATAM-LOWERS Novartis Corporation Consultant Fees/Honoraria Significant (>= \$5,000) Novo Nordisk Inc. Research/Research Grants Significant (>= \$5,000) Novo Nordisk Inc. Consultant Fees/Honoraria Significant (>= \$5,000) Spouse/Domestic Partner/Immediate Household Member	Prevention Prevention Prevention Prevention
Novartis Corporation Research/Research Grants # VICTORION-INCLUSION; LATAM-LOWERS Novartis Corporation Consultant Fees/Honoraria Significant (>= \$5,000) Novo Nordisk Inc. Research/Research Grants Significant (>= \$5,000) Novo Nordisk Inc. Consultant Fees/Honoraria Significant (>= \$5,000) Spouse/Domestic Partner/Immediate Household Member Florida Medical Associates, LLC Ownership Interest/Partnership/Principal Significant (>= \$5,000)	Prevention Prevention Prevention Prevention

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/1/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/1/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 10/1/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/1/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.